{"success":true,"data":{"pressRelease":{"id":"27419","rtpr_id":"nACSN9B3sa","ticker":"ATRA","exchange":"NASDAQ","all_tickers":["ATRA"],"title":"ATRA Shareholders Have Opportunity to Lead Atara Biotherapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!","author":"ACCESSWIRE","published_at":"2026-05-08T11:00:00.609Z","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May 8,\n2026 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized\ninvestor-rights law firm, announces that a class action lawsuit has been filed\nagainst Atara Biotherapeutics, Inc. (NASDAQ:ATRA) and certain of its officers.\n(https://app.accessnewswire.com/imagelibrary/ce6b9ca9-4f1a-4494-8107-b732f70faa16/bronstein-gewirtz-and-grossman-llc.png)\nThis lawsuit seeks to recover damages against Defendants for alleged\nviolations of the federal securities laws on behalf of all persons and\nentities that purchased or otherwise acquired Atara securities between May 20,\n2024 and January 9, 2026, both dates inclusive (the \"Class Period\"). Such\ninvestors are encouraged to join this case by visiting the firm's site:\nbgandg.com/ATRA.\n(https://bgandg.com/ATRA/?utm_source=accesswire&utm_medium=pressrelease&utm_campaign=ATRA)\n\nAtara Case Details\n\nThe complaint alleges defendants made false and/or misleading statements\nand/or failed to disclose that:\n1.\ncertain manufacturing issues, as well as deficiencies inherent in the ALLELE\nstudy, made it unlikely that the FDA would approve the tabelecleucel BLA;\n2.\naccordingly, tabelecleucel's regulatory prospects were overstated;\n3.\nthe aforementioned manufacturing issues also subjected Atara to a heightened\nrisk of regulatory scrutiny, as well as jeopardized its ongoing clinical\ntrials;\n4.\nall the foregoing was likely to have a significant negative impact on Atara's\nbusiness and financial condition; and\n5.\nas a result, Defendants' public statements were materially false and/or\nmisleading at all relevant times.\n\nWhat's Next for Atara Investors?\n\nA class action lawsuit has already been filed. If you wish to review a copy of\nthe Complaint, you can visit the firm's site: bgandg.com/ATRA.\n(https://bgandg.com/ATRA/?utm_source=accesswire&utm_medium=pressrelease&utm_campaign=ATRA)\nor you may contact Peretz Bronstein, Esq. or his Client Relations Manager,\nNathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911\n(tel:+9175900911). If you suffered a loss in Atara you have until May 22,\n2026, to request that the Court appoint you as lead plaintiff. Your ability to\nshare in any recovery doesn't require that you serve as lead plaintiff.\n\nNo Cost to Atara Investors\n\nWe, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on\na contingency fee basis. That means we will ask the court to reimburse us for\nout-of-pocket expenses and attorneys' fees, usually a percentage of the total\nrecovery, only if we are successful.\n\nWhy Bronstein, Gewirtz & Grossman, LLC for Atara Securities Class Action?\n\nBronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that\nrepresents investors in securities fraud class actions and shareholder\nderivative suits. Our firm has recovered hundreds of millions of dollars for\ninvestors nationwide. More at www.bgandg.com\n\n\"Our practice centers on restoring investor capital and ensuring corporate\naccountability, which serves to uphold the essential integrity of the\nmarketplace,\" said Peretz Bronstein\n(https://www.linkedin.com/in/peretz-bronstein-65a1b411), Founding Partner of\nBronstein, Gewirtz & Grossman, LLC.\n\nFollow us for updates on LinkedIn\n(https://www.linkedin.com/company/bronstein-gewirtz-&-grossman-llc/), X\n(https://x.com/bgandg_law), Facebook (https://www.facebook.com/BGandG/), or\nInstagram (https://www.instagram.com/bg_and_g/).\n\nContact Info\n\nPeretz Bronstein, Esq. or Nathan Miller\nBronstein, Gewirtz & Grossman, LLC\n917-590-0911 (tel:+9175900911) | info@bgandg.com\n\nAttorney advertising.\n\nPrior results do not guarantee similar outcomes.\n\nSOURCE: Bronstein, Gewirtz & Grossman, LLC\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/atra-shareholders-have-opportunity-to-lead-atara-biotherapeutics-1151342)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSN9B3sa","title":"ATRA Shareholders Have Opportunity to Lead Atara Biotherapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!","author":"ACCESSWIRE","ticker":"ATRA","created":"2026-05-08T11:00:00.609Z","tickers":["ATRA"],"exchange":"NASDAQ","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May 8,\n2026 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized\ninvestor-rights law firm, announces that a class action lawsuit has been filed\nagainst Atara Biotherapeutics, Inc. (NASDAQ:ATRA) and certain of its officers.\n(https://app.accessnewswire.com/imagelibrary/ce6b9ca9-4f1a-4494-8107-b732f70faa16/bronstein-gewirtz-and-grossman-llc.png)\nThis lawsuit seeks to recover damages against Defendants for alleged\nviolations of the federal securities laws on behalf of all persons and\nentities that purchased or otherwise acquired Atara securities between May 20,\n2024 and January 9, 2026, both dates inclusive (the \"Class Period\"). Such\ninvestors are encouraged to join this case by visiting the firm's site:\nbgandg.com/ATRA.\n(https://bgandg.com/ATRA/?utm_source=accesswire&utm_medium=pressrelease&utm_campaign=ATRA)\n\nAtara Case Details\n\nThe complaint alleges defendants made false and/or misleading statements\nand/or failed to disclose that:\n1.\ncertain manufacturing issues, as well as deficiencies inherent in the ALLELE\nstudy, made it unlikely that the FDA would approve the tabelecleucel BLA;\n2.\naccordingly, tabelecleucel's regulatory prospects were overstated;\n3.\nthe aforementioned manufacturing issues also subjected Atara to a heightened\nrisk of regulatory scrutiny, as well as jeopardized its ongoing clinical\ntrials;\n4.\nall the foregoing was likely to have a significant negative impact on Atara's\nbusiness and financial condition; and\n5.\nas a result, Defendants' public statements were materially false and/or\nmisleading at all relevant times.\n\nWhat's Next for Atara Investors?\n\nA class action lawsuit has already been filed. If you wish to review a copy of\nthe Complaint, you can visit the firm's site: bgandg.com/ATRA.\n(https://bgandg.com/ATRA/?utm_source=accesswire&utm_medium=pressrelease&utm_campaign=ATRA)\nor you may contact Peretz Bronstein, Esq. or his Client Relations Manager,\nNathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911\n(tel:+9175900911). If you suffered a loss in Atara you have until May 22,\n2026, to request that the Court appoint you as lead plaintiff. Your ability to\nshare in any recovery doesn't require that you serve as lead plaintiff.\n\nNo Cost to Atara Investors\n\nWe, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on\na contingency fee basis. That means we will ask the court to reimburse us for\nout-of-pocket expenses and attorneys' fees, usually a percentage of the total\nrecovery, only if we are successful.\n\nWhy Bronstein, Gewirtz & Grossman, LLC for Atara Securities Class Action?\n\nBronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that\nrepresents investors in securities fraud class actions and shareholder\nderivative suits. Our firm has recovered hundreds of millions of dollars for\ninvestors nationwide. More at www.bgandg.com\n\n\"Our practice centers on restoring investor capital and ensuring corporate\naccountability, which serves to uphold the essential integrity of the\nmarketplace,\" said Peretz Bronstein\n(https://www.linkedin.com/in/peretz-bronstein-65a1b411), Founding Partner of\nBronstein, Gewirtz & Grossman, LLC.\n\nFollow us for updates on LinkedIn\n(https://www.linkedin.com/company/bronstein-gewirtz-&-grossman-llc/), X\n(https://x.com/bgandg_law), Facebook (https://www.facebook.com/BGandG/), or\nInstagram (https://www.instagram.com/bg_and_g/).\n\nContact Info\n\nPeretz Bronstein, Esq. or Nathan Miller\nBronstein, Gewirtz & Grossman, LLC\n917-590-0911 (tel:+9175900911) | info@bgandg.com\n\nAttorney advertising.\n\nPrior results do not guarantee similar outcomes.\n\nSOURCE: Bronstein, Gewirtz & Grossman, LLC\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/atra-shareholders-have-opportunity-to-lead-atara-biotherapeutics-1151342)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-05-08T11:00:00.643427037Z","server_sent_at_ms":1778238000643},"received_at":"2026-05-08T11:00:00.851Z","source_url":"https://www.accessnewswire.com/newsroom/en/business-and-professional-services/atra-shareholders-have-opportunity-to-lead-atara-biotherapeutics-1151342"},"analysis":null,"durationMs":null,"modelName":null}}